Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.”

In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation.

Now, Jeff has found five under-the-radar stocks which could power your retirement.

P. Vagelos Biography and Net Worth

Director of Regeneron Pharmaceuticals

P. Roy Vagelos, MD, has been Chairman of the Board of the company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985 and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos was on the Board of Directors of Theravance, Inc. through April 2010. Dr. Vagelos is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society.

What is P. Roy Vagelos' net worth?: The estimated net worth of P. Roy Vagelos is at least $168.17 million as of August 11th, 2020. Dr. Vagelos owns 234,649 shares of Regeneron Pharmaceuticals stock worth more than $168,168,245 as of December 26th. This net worth approximation does not reflect any other assets that Dr. Vagelos may own. Learn More about P. Roy Vagelos' net worth.
How do I contact P. Roy Vagelos?: The corporate mailing address for Dr. Vagelos and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on P. Roy Vagelos' contact information.
Has P. Roy Vagelos been buying or selling shares of Regeneron Pharmaceuticals?: P. Roy Vagelos has not been actively trading shares of Regeneron Pharmaceuticals over the course of the past ninety days. Most recently, P Roy Vagelos sold 10,039 shares of the business's stock in a transaction on Wednesday, August 18th. The shares were sold at an average price of $650.04, for a transaction totalling $6,525,751.56. Learn More on P. Roy Vagelos' trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 106,315 shares worth more than $104,138,555.84. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

P. Roy Vagelos Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/18/2021	Sell	10,039	$650.04	$6,525,751.56
8/11/2020	Sell	33,460	$602.94	$20,174,372.40	234,649
5/21/2020	Sell	783	$577.49	$452,174.67	307,849
12/13/2019	Sell	51,842	$376.04	$19,494,665.68	412,140
11/25/2019	Sell	22,149	$363.83	$8,058,470.67
12/12/2018	Sell	6	$382.32	$2,293.92	387,449
7/10/2018	Sell	74,670	$367.22	$27,420,317.40	553,121
6/21/2018	Sell	74,710	$327.87	$24,495,167.70	553,121
8/22/2017	Sell	56,213	$474.48	$26,671,944.24	363,638
8/18/2017	Sell	15,191	$470.15	$7,142,048.65	329,543
8/17/2017	Sell	1,305	$470.00	$613,350.00	329,543
8/16/2017	Sell	10,986	$470.17	$5,165,287.62	329,543
5/25/2017	Sell	9,295	$458.14	$4,258,411.30	414,156
11/18/2015	Sell	17,240	$587.90	$10,135,396.00	332,880
11/3/2015	Sell	17,242	$580.19	$10,003,635.98	351,851
9/10/2014	Sell	10,328	$350.07	$3,615,522.96
8/13/2014	Sell	8,028	$340.01	$2,729,600.28
8/11/2014	Sell	11,972	$340.11	$4,071,796.92
2/11/2014	Sell	11,475	$325.10	$3,730,522.50	69,960
9/19/2013	Sell	145,356	$302.86	$44,022,518.16	65,759
5/6/2013	Sell	12,018	$263.15	$3,162,536.70
11/27/2012	Sell	64,753	$175.22	$11,346,020.66

P. Roy Vagelos Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $716.68

$709.08

$718.49

50 Day Range

MA: $803.10

$701.85

$998.23

2 Week Range

Now: $716.68

$693.00

$1,211.20

Volume

619,236 shs

Average Volume

569,007 shs

Market Capitalization

$78.76 billion

P/E Ratio

17.74

Dividend Yield

N/A

Beta

0.08

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>